The Role of Cancer Stem Cells in Drug Resistance in Gastroesophageal Junction Adenocarcinoma

Kate Dinneen¹,²*, Anne-Marie Baird¹, Ciara Ryan² and Orla Sheils¹

¹School of Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland, ²Department of Histopathology, St. James’s Hospital, Dublin, Ireland

Gastroesophageal junction adenocarcinomas (GEJA) have dramatically increased in incidence in the western world since the mid-20th century. Their prognosis is poor, and conventional anti-cancer therapies do not significantly improve survival outcomes. These tumours are comprised of a heterogenous population of both cancer stem cells (CSC) and non-CSCs, with the former playing a crucial role in tumorigenesis, metastasis and importantly drug resistance. Due to the ability of CSCs to self-replicate indefinitely, their resistance to anti-cancer therapies poses a significant barrier to effective treatment of GEJA. Ongoing drug development programmes aim to target and eradicate CSCs, however their characterisation and thus identification is difficult. CSC regulation is complex, involving an array of signalling pathways, which are in turn influenced by a number of entities including epithelial mesenchymal transition (EMT), microRNAs (miRNAs), the tumour microenvironment and epigenetic modifications. Identification of CSCs commonly relies on the expression of specific cell surface markers, yet these markers vary between different malignancies and indeed are often co-expressed in non-neoplastic tissues. Development of targeted drug therapies against CSCs thus requires an understanding of disease-specific CSC markers and regulatory mechanisms. This review details the current knowledge regarding CSCs in GEJA, with particular emphasis on their role in drug resistance.

Keywords: cancer stem cells, drug resistance, gastroesophageal junction adenocarcinoma, epithelial mesenchymal transition, microRNA

INTRODUCTION

Gastroesophageal junction adenocarcinomas (GEJA) are cancers which straddle the junction between the oesophagus and stomach, sharing similar epidemiological characteristics and risk factors to oesophageal adenocarcinoma (OAC) (Bray et al., 2018). Globally, these cancers have an average 5-year survival rate of 19.9% (Seer, 2019). Their incidence has increased by approximately 600% since the 1970s, with the majority of cases occurring in the Western world (Rubenstein and Shaheen, 2015). This epidemiological shift can be partially accounted for by changes in Western lifestyle including diet, increased rates of obesity, smoking and gastro-oesophageal reflux disease; however, the precise cause remains unclear (Buas and Vaughan, 2013). Despite early advances in treatment modalities, rates of disease recurrence and resistance to anti-cancer therapies remain high (Brungs et al., 2019), highlighting the need for further research into the epidemiology, management, molecular biology and classification of these tumours. This review focuses on drug therapies in GEJA,
with a specific emphasis on the role of cancer stem cells (CSC) in the development of drug resistance and their potential utility as targets for novel anti-cancer therapies in GEJA.

The Argument for GEJA as a Distinct Entity
Much of our current knowledge about GEJA is inferred from studies conducted on oesophageal and gastric adenocarcinomas. Malignancies of the gastroesophageal junction (GEJ) have traditionally been subdivided into cancers of either gastric or oesophageal origin. Clinical classification is based on the Siewert scoring system, which categorises tumours into three groups according to the location of their epicentre in relation to the gastric cardia: the epicentre of Siewert I tumours are 1-5 cm above; Siewert II tumour epicentres lie between 1 cm above and 2 cm below, and the epicentre of Siewert III tumours lies 2-5 cm below the gastric cardia (Siewert and Stein, 1998). By contrast, the TNM staging system is used to determine pathological classification. Whilst the 7th edition of the TNM staged all GEJ tumours as oesophageal cancers, the 8th edition was revised to treat Siewert II tumours as gastric cancers, similar to the original definition (Rice et al., 2017; Zanoni et al., 2018). However, many now believe that GEJ malignancies are best regarded as a separate disease entity with a distinct genetic signature, which could facilitate more accurate classification through a “cell of origin” model in the future (Hayakawa et al., 2016; Rice et al., 2017; Abdi et al., 2019; Lin et al., 2019). Indeed, the pathogenesis of OAC (Siewert I-II) and intestinal type adenocarcinoma of the gastric cardia (Siewert III) both arise in the setting of intestinal metaplasia, indicating potential shared carcinogenic pathways between the two anatomical locations. This pathological link is further supported by genetic studies, which suggest that metaplastic cells in Barrett’s oesophagus originate not from squamous progenitor cells, but rather from gastric cardia progenitor cells that have migrated to the lower oesophagus (Paulson et al., 2006; Quante et al., 2012). Additionally, recent genetic profiling studies demonstrated genetic similarities between chromosomal unstable subtype (CIN) gastric cardia adenocarcinomas and oesophageal adenocarcinoma of the GEJ (Bass et al., 2014; Kim et al., 2017).

Current Treatment Options
Current treatment options for GEJA depend on the disease stage at diagnosis. Locally advanced non-metastatic GEJA is treated with a multimodal approach, usually a combination of surgical resection with neoadjuvant, perioperative and/or adjuvant chemotherapy, with or without concomitant radiotherapy (Lin et al., 2019). In early stage disease (Tis, T1a), minimally invasive approaches using endoscopic mucosal or submucosal resections may be possible, whilst frankly invasive tumours (T1b-4) require surgical resection. Surgery alone has unacceptably high rates of treatment failure, often due to advanced stage at presentation, thus most patients receive additional neoadjuvant or perioperative therapy such as Fluorouracil and Cisplatin. Several trial studies have examined these treatment options in lower oesophageal and gastric adenocarcinomas, both alone and in combination with surgery, from which data relating to GEJA has been extrapolated (Table 1). Whilst each showed a modest improvement in survival outcomes, the rates of overall survival (OS) and complete pathologic response (CPR) remained poor (Al-Batran et al., 2016). Approximately 55-60% of patients with early stage disease who undergo primary resection with curative intent will relapse within 5 years, and the median OS for patients with metastatic/recurrent disease is 11-12 months (Joshi et al., 2018). The poor response to these conventional therapies highlights a need for the development of more effective targeted therapies for both early and advanced stage disease.

Early advances in our understanding of the molecular biology of GEJA have identified potential new treatment targets (Maron and Catenacci, 2017). Molecularly defined GEJ subsets have been observed that may hold therapeutic relevance, including tumours related to Epstein-Barr Virus; tumours with hyper-mutation, in particular microsatellite instable tumours; and those with homologous recombination deficiency (Janjigian et al., 2018). Many GEJAs are of CIN subtype, with amplifications in a range of receptor tyrosine kinases (RTKs), including EGFR and ERBB2 (Bass et al., 2014; Cristescu et al., 2015; Secrion et al., 2016; Kim et al., 2017). An additional class of drug which shows promise in GEJA are immune checkpoint inhibitors (ICIs), which help the immune system to attack cancer cells. Immunotherapeutic agents such as Pembrolizumab have been approved for use in chemotherapy refractory GEJA (Le et al., 2015; Muro et al., 2016; Janjigian et al., 2018; Greally et al., 2019). Ongoing trials

### Table 1: Completed Trial Outcomes for Current GEJA Treatments.

| Study Name and Design | Survival Data | Clinical Trial Number |
|-----------------------|---------------|-----------------------|
| Neoadjuvant chemoradiotherapy plus surgery vs. surgery alone for oesophageal or junctional cancer (CROSS) (Shapiro et al., 2015). | Median OS 43.2 months vs. 27.1 months for surgery alone | Netherlands trial register number NTR487 |
| Perioperative Epirubicin, Cisplatin, and Infused Fluorouracil vs. surgery alone for incurable gastric, lower oesophageal or GEJ cancer (MAGIC) (Cunningham et al., 2006). | 5-year survival 38% vs. 23% for surgery alone | Current controlled trials number ISRCTN93793971 |
| Perioperative Fluorouracil + Cisplatin in resectable GEJA (ACCORD) (Ychou et al., 2011). | Median OS 50 months vs. 35 months in control ECF/ECX group | Clinical trials gov number NCT00002983 |
| Perioperative chemotherapy with Fluorouracil + Leucovorin, Oxaliplatin, and Docetaxel vs. ECF or ECX for resectable gastric or GEJ adenocarcinoma (FLOT4) (Al-Batran et al., 2019). | | Clinical trials gov number NCT01216644 |

**Abbreviations:** OS, overall survival; ECF, Epirubicin, Cisplatin, and Fluorouracil; ECX, Epirubicin, Cisplatin, Capecitabine.
are focusing on combinations of ICIs with established adjunct therapies, in addition to investigating the utility of novel drugs such as Ramucirumab—a vascular endothelial growth factor receptor 2 (VEGFR2) antagonist (Table 2). Whilst these trials have shown modest therapeutic benefits, the survival advantage for the patient nevertheless remains low. The fact that most trials focus on patients with disease refractory to first line therapies emphasises the ongoing issue of complex resistance mechanisms which circumvent anti-cancer drug treatments.

### Mechanisms of Treatment Resistance

Resistance to anti-cancer therapies persists as an obstacle to optimal clinical management and prognostication in GEJA. The mechanisms leading to drug resistance are complex and multifactorial, and the pharmacological impact of a particular therapeutic agent depends on both intrinsic and acquired tumour cell characteristics (Vasan et al., 2019), (Figure 1). For example, the interplay between the tumour and its microenvironment—that being the surrounding immune cells, stroma and vasculature—may mediate resistance through obstruction of drug absorption by the tumour cells or by stimulation of paracrine growth factors that promote tumour cell growth (Prieto-Vila et al., 2017; Vasan et al., 2019). Physical barriers include “sanctuary sites”, which are anatomical sites within which systemic therapies do not reach therapeutic concentrations (Toyokawa et al., 2015). The central nervous system is the main sanctuary site in the human body, with the blood brain barrier acting as a physical barrier; however, sanctuary sites may also exist at tissue level due to uneven drug distribution between different tissue types. Furthermore, across many different types of cancers there exists a number of oncogenes and tumour

### Table 2 | Ongoing Phase 3 Trials of Targeted Therapies in GEJA.

| Clinical Trials Identifier Number | Phase Line | Disease Types | Intervention | Primary Endpoints |
|----------------------------------|------------|---------------|--------------|------------------|
| NCT02370498 | III II | Gastric and GEJ adenocarcinoma | Pembrolizumab vs. Paclitaxel in patients who progressed after therapy with Platinum and Fluoropyrimidine | PFS and OS |
| NCT03019588 | III II | Advanced gastric and GEJ adenocarcinoma | Pembrolizumab vs. Paclitaxel in patients who progressed after therapy with Platinum and Fluoropyrimidine | PFS and OS |
| NCT02314117 | III I | Metastatic gastric and GEJ adenocarcinoma | Capecitabine and Cisplatin +/- Ramucirumab | PFS |
| NCT02494583 | III I | Advanced gastric and GEJ adenocarcinoma | Pembrolizumab vs. Pembrolizumab + 5-FU or Capecitabine vs. Placebo + 5-FU or Capecitabine | PFS and OS |
| NCT01196390 | III I | Oesophageal and GEJ adenocarcinoma | Radiation therapy, Paclitaxel and Carboplatin +/- Trastuzumab | DFS |
| NCT02625610 | III I | Unresectable gastric and GEJ adenocarcinoma | Avelumab vs. continuation of first line chemotherapy | OS |
| NCT02591462 | III I | Gastric and GEJ adenocarcinoma | FLOT vs. FLOT + Herceptin/Pertuzumab | PFS and CPR |
| NCT02684263 | III II | Advanced oesophageal and GEJ adenocarcinoma | Pembrolizumab vs. investigator’s choice standard therapy | OS |
| NCT02661971 | III I | Gastric and GEJ adenocarcinoma | FLOT vs. FLOT/Ramucirumab | OS and CPR |
| NCT03221426 | III I | Localized gastric and GEJ adenocarcinoma | Pembrolizumab + Chemotherapy (FP or XP) vs. Placebo + Chemotherapy (FP or XP) | OS, EFS and CPR |
| NCT02743494 | III I | Oesophageal and GEJ adenocarcinoma | Nivolumab vs. Placebo | DFS and OS |

Abbreviations: GEJ, gastroesophageal junction; FP, 5-fluorouracil; XP, Cisplatin plus Capecitabine; EFS, event free survival; DFS, disease free survival; PFS, progression free survival; CPR, complete pathologic response.

---

**Figure 1 | Mechanisms of drug resistance.** Multiple different mechanisms contribute to the development of drug resistance in cancer. These include the interaction between the tumour and its microenvironment; secretion of paracrine growth factors which promote tumour growth; tumour heterogeneity; physical barriers and the ‘undruggable genome’, which refers to mutations which have not yet been targeted by anti-cancer therapies. The blue cells in the background are B lymphocytes. The green cells in the background are T lymphocytes. The bright green cells in the tumour mass are cancer stem cells.
suppressor genes, many of which have yet to be targeted by anti-cancer therapies, including TP53 and MYC: the presence of this “undruggable genome” further contributes to tumour cell heterogeneity and hence drug resistance (Vasan et al., 2017).

Most tumours are comprised of a phenotypically diverse population of cancer cells, driven by a complex array of genetic and phenotypic alterations that disrupt normal cell cycle and cellular processes at multiple levels, including genomic, transcriptomic and influences from the tumour microenvironment (Prasetyanti and Medema, 2017; Shibue and Weinberg, 2017; Sharma et al., 2019; Tripathi et al., 2020). This diversity is known as intra-tumour heterogeneity and is thought to play a crucial role in the development of treatment resistance (Prasetyanti and Medema, 2017). Putative personalised therapies often fail because a single biopsy may sample only one sub-population of tumour cells, thus understimating the heterogeneity present within a tumour (Gerlinger et al., 2012). Contributing to this complex heterogeneity is the presence of cancer stem cells (CSCs). This tumour cell population is of critical clinical importance and is known to contribute to resistance to anti-cancer therapies in many solid organ malignancies (Li and Li, 2014; Nunes et al., 2018).

Cancer Stem Cells

CSCs are a small but crucially important sub-population of tumour cells which drive tumorigenesis, metastasis and treatment resistance (Prasetyanti and Medema, 2017). They are undifferentiated and capable of limitless self-renewal, with potential for subsequent differentiation into various non-CSC cell types which lack capacity for self-renewal or migration and instead form the bulk of the tumour (Reya et al., 2001). They were first identified in the 1990s when CD34+, CD38− leukemic cells were shown to have bone marrow hematopoietic stem cell characteristics (Lapidot et al., 1994; Bonnet and Dick, 1997). In the 2003 seminal paper, Al-Hajj et al identified CSCs in solid tumours by demonstrating tumorigenic (stem) cells with cell surface marker profile CD44+, CD24−/low in breast cancer (Al-Hajj et al., 2003). Shortly after, CSC markers were identified for other malignancies including prostate, colon, liver and lung (Medema, 2013; Eun et al., 2017).

CSCs hold a Darwinian survival advantage over other subclones within a single tumour due to their endogenous resistance against chemo-radiotherapy regimes (Eun et al., 2017; Prieto-Vila et al., 2017). Their ability to generate phenotypically varied clonal populations within a single tumour increases the likelihood of at least one group of tumour cells surviving the assault of anti-cancer treatments (Brooks et al., 2015; Eun et al., 2017). It has been proposed that the limited efficacy of conventional anti-cancer therapies is attributable to the fact that these treatments target the bulk population of non-CSCs within a tumour, allowing small populations of CSCs to persist and propagate, leading to a clinical relapse (Reya et al., 2001; Shibue and Weinberg, 2017), (Figure 2). CSCs are therefore one of the most clinically important contributors to intra-tumour heterogeneity and thus resistance to anti-cancer treatments.

CSCs have recently been shown to possess the ability to dynamically switch between CSC and non-CSC states. This cellular plasticity is regulated by a number of extrinsic and intrinsic factors (Batle and Clevers, 2017). Extrinsic factors include niches, which are a specialised component of the tumour microenvironment which act to regulate the fate of stem cells via extrinsic signals and cellular interactions, allowing them to interconvert between differentiated and stem-like states (Quail et al., 2012; Cabrera et al., 2015). In addition to this, intrinsic factors at both the genetic and epigenetic level are also implicated, including regulatory transcription factors (TF), DNA methylation and histone modifications (Thankamony et al., 2020). CSCs are regulated by a number of signalling pathways associated with stemness, including Notch, Hedgehog, Wnt/β-Catenin, JAK/STAT, and NF-κB (Chen et al., 2013a). These pathways play a role in the maintenance of stem cell properties and/or regulation of their differentiation through alteration of messenger RNA (mRNA) expression via a specific subset of TFs including OCT3/4, SOX2, c-MYC and Klf-4 (Takahashi and Yamanaka, 2006; Eun et al., 2017). These TFs, amongst others, are thought to act in concert with each other and additional complex molecular processes, including regulatory microRNAs (miRNA), to establish CSC traits in neoplastic cells. The overlapping influences upon CSC plasticity clearly demonstrate the
miRNAs involved in CSC regulation include the miR-17-92 family, which regulates the MYC oncogene to protect CSCs against apoptosis; the let-7 family, whose decreased expression is associated with metastasis and chemoresistance; and a wide range of others including miR-21, miR-16 and miR-200 (Li et al., 2014; Mens and Ghanbari, 2018). Although many miRNA families have been shown to regulate organ-specific CSCs, there is considerable overlap between the expression of miRNAs in different solid organ malignancies (Chakraborty et al., 2016). For example, miR-17 is downregulated in OAC and renal cell carcinoma CSCs, yet miR-17 over-expression has been demonstrated in colorectal CSCs (Lichner et al., 2015; Xi et al., 2016). This highlights the molecular complexities of CSC characteristics (Khan et al., 2019). In their latter role, they act by targeting many of the mRNAs which are associated with stemness properties (Khan et al., 2019). Certain miRNAs may also contribute to tumorigenesis by regulating the cell cycle components of CSCs to inhibit apoptosis and promote cellular proliferation (Mens and Ghanbari, 2018).

miRNAs as Regulators of CSC
miRNAs are a class of small non-coding RNAs which are involved in regulating gene expression through either degradation of their target mRNA or inhibition of mRNA translation, with an overall effect of altered protein expression within cells (Hezova et al., 2016). miRNAs are key in regulating a range of essential biological processes including proliferation, differentiation, survival and apoptosis in many different cell types (Hezova et al., 2016). They have been shown to be aberrantly expressed in various human cancers and play a part in the regulation of CSC characteristics (Khan et al., 2019). In their latter role, they act by targeting many of the mRNAs which are associated with stemness properties (Khan et al., 2019). Certain miRNAs may also contribute to tumorigenesis by regulating the cell cycle components of CSCs to inhibit apoptosis and promote cellular proliferation (Mens and Ghanbari, 2018).

Table 3 lists a number of miRNAs known to play a role in regulating gastric and oesophageal CSCs.

**Table 3** | List of miRNAs Involved in Regulating Gastric and Oesophageal CSCs.

| miRNA ID | Tumour Type       | Pattern of Expression | Functional Significance | Reference                  |
|----------|-------------------|-----------------------|------------------------|----------------------------|
| miR-15a-3p | Gastric adenocarcinoma | Downregulated        | Tumour suppressor      | (Wang et al., 2017)        |
| miR-16-1-3p | Gastric adenocarcinoma | Downregulated        | Tumour suppressor      | (Wang et al., 2017)        |
| miR-17-5p  | OAC                | Downregulated        | Enhanced radioresitivity| (Lynam-Lennon et al., 2017) |
| miR-10b    | Gastric adenocarcinoma, OAC | Upregulated, Upregulated | Oncomir                | (Wang et al., 2013); (Tian et al., 2010) |
| miR-200a   | Gastric adenocarcinoma, OAC | Downregulated        | Oncomir                | (Chen et al., 2015c)       |
| miR-146b-5p| Gastric adenocarcinoma | Upregulated           | Oncomir                | (Lj et al., 2018)          |
| miR-93-5p  | Gastric adenocarcinoma | Upregulated           | Tumour suppressor, Oncomir | (Chen et al., 2015c)       |
| miR-219-5p | Gastric adenocarcinoma | Downregulated        | Tumour suppressor      | (Lj et al., 2017)          |
| miR-193-3p | Gastric adenocarcinoma | Downregulated        | Tumour suppressor      | (Jian et al., 2018)        |
| miR-192    | Gastric adenocarcinoma | Downregulated        | Tumour suppressor      | (Chiang et al., 2012)      |
| miR-215    | Gastric adenocarcinoma | Downregulated        | Tumour suppressor      | (Chiang et al., 2012)      |
| miR-221    | OAC                | Upregulated           | Enhanced chemoresistance| (Wang et al., 2016)        |

Abbreviations: miRNA, microRNA; miR, microRNA; OAC, oesophageal adenocarcinoma.

Barriers posed to the development of effective anti-cancer drug therapies for GEJA and other malignancies.

**MicroRNAs as Regulators of CSC**
miRNAs are a class of small non-coding RNAs which are involved in regulating gene expression through either degradation of their target mRNA or inhibition of mRNA translation, with an overall effect of altered protein expression within cells (Hezova et al., 2016). miRNAs are key in regulating a range of essential biological processes including proliferation, differentiation, survival and apoptosis in many different cell types (Hezova et al., 2016). These mediators are involved in the activation of a group of miRNAs involved in CSCs, including proliferation, differentiation, survival and apoptosis. These processes are tightly regulated by overlapping signalling pathways.

**EMT as a Regulator of CSC**
Epithelial mesenchymal transition (EMT) is also believed to play a crucial role in the regulation of CSCs. First described in 1982 by Greenberg and Hay (Greenburg and Hay, 1982), it is a process of lineage transition whereby epithelial cells lose their adhesive properties and acquire a mesenchymal cell phenotype, with corresponding changes in cell morphology and expression of surface markers (Kalluri and Weinberg, 2009). This phenotypic change in neoplastic cells facilitates tumour cell invasion, metastasis and drug resistance (Lamouille et al., 2014; Chen et al., 2017), (Figure 3).

EMT itself is tightly regulated by a wide spectrum of complex cellular signalling pathways. The tumour microenvironment—comprised of a large cohort of stromal cells including cancer associated fibroblasts (CAF), T-lymphocytes, macrophages and myeloid derived suppressor cells—releases a range of cytokines, chemokines and growth factors which act in a paracrine fashion to induce EMT (Kalluri and Weinberg, 2009; Dongre and Weinberg, 2019). These mediators are involved in the activation of a group of EMT-TFs, including the Zeb, Snail, Twist and FOXC families.
and a poor clinical prognosis (Jolly et al., 2019). Efforts have thus recently been shown to correlate with tumour aggressiveness (Medici et al., 2008; Kalluri and Weinberg, 2009; Galvan et al., 2015; Wei et al., 2015; Yu et al., 2015). Once activated, they orchestrate the EMT programme through a series of frequently overlapping intracellular signalling pathways including MAPK, ERK, PI3K, SMADs and Wnt/β-catenin (Tse and Kalluri, 2007; Kalluri and Weinberg, 2009). These pathways are further regulated by multiple intricate cellular interactions involving miRNAs, epigenetic modulators and exogenous inducers (Chen et al., 2017). The TFs, signalling pathways and indeed the regulatory miRNAs which govern EMT have been shown to intersect with those involved in the regulation of CSC characteristics.

An association between EMT and CSC traits was first proposed as an explanation for the ability of tumour cells at the invasive tumour front to metastasize to distant sites (Brabletz, 2012). This relationship has been extensively investigated, with early experimental studies demonstrating an association between EMT and CSC traits in neoplastic cells across a wide range of human carcinomas (Chen et al., 2017). In 2008 Mani et al were the first to demonstrate a direct link between EMT and CSCs by inducing EMT in human mammary epithelial cells (HMLE) via ectopic expression of Snail or Twist, or exposure to TGF-β stimulation. Following this, expression of a mesenchymal phenotype and acquisition of stemness traits was witnessed: cells acquired a CD44-high/CD24-low phenotype with the ability to form a mammosphere (Mani et al., 2008). Morel et al similarly demonstrated the acquisition of CSC traits in HMLEs following activation of the Ras-MAPK pathway, which is involved in EMT (Morel et al., 2008). However, these in vitro studies induced pure epithelial and mesenchymal states, leading to the assumption that the EMT programme represented a binary switch between phenotypic states, with mesenchymal cells believed to represent CSCs and epithelial cells non-CSCs. Recent evidence now indicates that EMT is best viewed as along continuum, whereby some cancer cells may undergo partial EMT, resulting in a hybrid epithelial/mesenchymal (E/M) phenotype (Grosse-Wilde et al., 2015; Beerling et al., 2016; Nieto et al., 2016; Bierie et al., 2017; Kröger et al., 2019).

This E/M state, rather than the pure mesenchymal phenotype, has recently been shown to correlate with tumour aggressiveness and a poor clinical prognosis (Jolly et al., 2019). Efforts have thus been made to identify the molecular components which promote and regulate this hybrid state, which are referred to as phenotypic stability factors (PSF). Bocci et al demonstrated that high expression of nuclear factor erythroid 2-related factor 2 (NRF2) is involved in stabilising the hybrid E/M phenotype, which in turn correlated with poor survival outcomes (Bocci et al., 2019). Additional studies identified GRHL2, OVOL2, NUMB and ΔNp63α as other important PSFs (Watanabe et al., 2014; Dang et al., 2015; Jolly et al., 2016; Bocci et al., 2017). Expression of these factors, in tandem with the EMT-TFs described above, have been shown to facilitate cell migration by preventing cells from undergoing complete EMT. Further interrogation of this model of cellular plasticity is required in order to improve our understanding of cancer progression, metastasis and potentially mechanisms of resistance to anti-cancer drug therapies in GEJA and other malignancies.

Interestingly, both EMT and CSCs are also associated with tumour budding, which is defined as the presence of isolated tumour cells or clusters of up to four tumour cells present in the stroma at the invasive tumour front (Lino-Silva et al., 2018). Tumour buds (TB) are thought to represent the histological correlate of EMT, as they may transiently acquire a mesenchymal phenotype due to activation of the WNT signalling pathway, with associated loss of membranous e-cadherin expression and gain of strong nuclear beta-catenin staining (Zlobec and Lugli, 2010). TBs in colorectal cancer have also been shown to express stem cell markers including LGR5, ALDH1 and CD44, indicating a link between transition to the mesenchymal phenotype and acquisition of stemness traits (Lugli et al., 2020). The presence of TBs has demonstrated utility as a prognostic tool, correlating with risk of disease relapse and death from disease in upper gastrointestinal tumours including OAC and GEJA (Brown et al., 2010; Koelzer et al., 2014; Landau et al., 2014), whilst their potential as a predictive tool remains under investigation. Furthermore, TBs are associated with resistance to conventional anti-cancer therapies, which may be explained by their low proliferative activity and resistance to apoptosis due to up-regulation of anti-apoptotic proteins including RAF-kinase inhibitor protein (RKIP) (Dawson et al., 2014). The presence of these cells in epithelial malignancies, including GEJA, clearly holds potential as a future oncotarget.

### THE ROLE OF EMT AND CSC IN DRUG RESISTANCE

Intra-tumour heterogeneity contributes to the efficacy of anti-cancer drug therapies through intrinsic and acquired drug resistance, which develops as a result of both genetic and epigenetic alterations of sub-populations of cancer cells within the tumour mass (Esteller, 2008; Shibue and Weinberg, 2017). The relative sensitivities of isolated CSC-enriched tumour subpopulations to chemotherapy, radiotherapy, immunotherapy and molecularly targeted therapies have been extensively investigated, with analyses demonstrating a far greater survival of CSCs compared to non-CSCs across all treatment modalities and across multiple different cancer types (Graham et al., 2002; Levina et al., 2008; Dallas et al., 2009; Shibue and Weinberg, 2017).

EMT activation confers resistance to many different types of therapeutic agents through a range of mechanisms, including elevated expression of anti-apoptotic proteins such as Bcl-XL; slow stem cell proliferation rates and increased levels of ATP-binding cassette (ABC) transporters that mediate drug reflux (Singh and Settleman, 2010; Shibue and Weinberg, 2017). For example, Snail and Slug confer resistance to chemotherapy in many cancers through antagonization of p53-mediated apoptosis and by regulation of other genes involved in cell death (Dongre and Weinberg, 2019). The miR-200 family play a contributory role in treatment resistance, restoring chemosensitivity in aggressive cancer cells through reversal of EMT (Cochrane et al., 2010). This association is further corroborated by studies which demonstrated a strong link between treatment
resistance and the altered expression of genes associated with EMT in cancer cells (Farmer et al., 2009; Byers et al., 2013).

Early results from clinical trials indicate that CSCs play a key role in regulation of resistance to anti-cancer drugs. A phase II clinical trial of patients with gastric cancer showed that patients who received chemotherapy with Vismodegib—a hedgehog inhibitor—held a survival advantage if their tumour had high expression of CSC marker CD44 (Yoon et al., 2014). The use of immunotherapy approaches to target CSCs are also under investigation, focusing on therapies which target the CSC traits of immune resistance and immunosuppression (Codd et al., 2018). Despite these early advances, a greater understanding of the relationship between EMT, CSCs and their mechanisms of drug resistance would undoubtedly enhance drug development and clinical outcomes for patients.

CSC Markers in GEJA

Therapeutic targeting of CSCs is limited by difficulties in characterization of appropriate CSCs across many solid and haematological malignancies. A range of markers have been recognised for identification of CSCs, including cell surface markers CD133, CD44, CD24 and CD66 and ALDH1A1 (Prasetyanti and Medema, 2017). Unsurprisingly, given their shared characteristics, the markers used to isolate CSCs overlap greatly with those used in the identification of normal adult stem cells in non-neoplastic tissues (Brungs et al., 2016). Their clinical utility is somewhat hampered by the fact that expression of CSC markers is not uniform across different malignancies: heterogenous expression may be observed within a single tumour, between cancer subtypes and even between patients within the same tumour subtype (Visvader and Lindeman, 2012). Furthermore, the inherent plasticity in the process of acquisition of CSC traits further complicates the isolation of CSCs for further study.

Several studies exist within the literature regarding the identification, regulation and clinicopathologic characteristics of CSCs and CSC-like cells in both gastric and oesophageal cancers, amongst a wide range of other malignancies. Whilst studies pertaining specifically to CSCs in GEJA are sparse, it must be remembered that studies investigating the role of CSCs in both OAC and gastric cardia adenocarcinomas will include a proportion of GEJAs. Here we describe some of the most common CSC markers used in gastric and oesophageal malignancies.

CD133

CD133, also known as Prolamin-1, is a five transmembrane glycoprotein plasma membrane protein that has been used to identify putative CSCs in a range of tumours including colon, pancreas, prostate, stomach and oesophagus (Brungs et al., 2016). It plays a role in regulation of the lipid component of the plasma membrane, yet its precise function remains unknown (Codd et al., 2018). Whilst frequently used as a marker of CSCs, CD133 is not a CSC-specific antigen as it is also expressed in a number of differentiated epithelial cells in various organs (Wu and Wu, 2009). The use of different CD133 clones complicates comparisons between studies, leading to poor reducibility and potential for erroneous results (Hermansen et al., 2011). Despite this, an early study investigating the utility of CD133 as a target for anti-CSC therapies in ovarian cancer has shown promising results (Skubitz et al., 2013).

A meta-analysis investigated the correlation between CD133+ gastric cancers and clinical outcomes in 773 patients, identifying worse cumulative 5 year OS rates in CD133+ patients (21.4%) as compared with CD133- patients (55.7%), in addition to a close correlation between CD133 over-expression and adverse clinicopathological features (Wen et al., 2013). A more recent study demonstrated higher levels of CD133+ cells in blood samples from gastric cancer patients, which correlated with poor prognosis, as compared to unmatched normal controls (Xia et al., 2015).

The role of CD133 in drug resistance has been described through analysis of the ability of SP1049C—a pluronic-based micellar formulation of Doxorubicin that has demonstrated safety and efficacy in patients with advanced OAC and GEJA in a phase II trial—to deplete CD133+ CSCs and decrease cancer cell tumorigenicity in vivo (Alakhova et al., 2013). These findings suggest a link between CD133+ CSCs and drug resistance in OAC.

CD44

CD44 is a transmembrane glycoprotein that is expressed on both CSCs and differentiated adult cells, including endothelial cells and hepatocytes, thus it cannot be regarded as a CSC-specific antigen. It has a wide range of physiological roles including adhesion, migration, differentiation, growth and survival (Ponta et al., 2003). It serves as a putative CSC marker in a range of malignancies including colon, brain, stomach and oesophagus (Brungs et al., 2016). CD44 is encoded by the 20 exon CD44 gene, which is subject to alternative splicing (Lau et al., 2014). It has been proposed that CD44 variants (CD44v) are more specific in their identification of cells with tumorigenic potential when compared to the standard isoform (CD44s) (Thapa and Wilson, 2016). A number of studies have identified CD44v in metastatic deposits from a range of solid organ malignancies, which were associated with a poorer prognosis (Mulder et al., 1994; Kaufmann et al., 1995; Ni et al., 2014; Ozawa et al., 2014). Specific CD44 isoforms have been identified as potential targets for anti-cancer therapies: early studies are investigating the potential for therapeutic targeting of CD44+ CSCs in breast cancer (Aires et al., 2016).

CD44v6 expression in gastric cancer resection specimens is associated with poorer clinical outcomes including distant metastasis, lymph node metastasis and death of invasion (Liu et al., 2005; Chen et al., 2013b). CD44+ circulating tumour cells (CTCs) in patients with gastric cancer were also shown to correlate with the clinicopathologic characteristics of the resected tumour specimens, including disease stage and venous invasion, whilst CD44- CTCs did not (Watanabe et al., 2017). The association between loss of CD44 expression and poor survival outcomes in patients with OAC has also been described (Honing et al., 2014). These findings suggest that CD44 is useful as a putative CSC marker and a predictor of patient outcomes in gastric adenocarcinoma and OAC.
ALDH1

Within the human genome, the aldehyde dehydrogenase (ALDH) family comprises a reported 19 functional genes which encode enzymes involved in the oxidative metabolism of endogenous and exogenous aldehyde substrates, including lipids and amino acids (Tomita et al., 2016). ALDH1 has 3 isoforms (ALDH1A1, ALDH1A2 and ALDH1A3) and is a marker of both stem cells and CSCs, with expression observed in colon, pancreas, breast and prostate cancers (Brungs et al., 2016; Tomita et al., 2016). ALDH1 has been shown to attenuate oxidative stress: CSCs contain lower levels of reactive oxygen species (ROS) than differentiated tumour cells, allowing them to survive under conditions of metabolic and oxidative stress (Vassalli, 2019). The ALDH family is in fact a target of the TF NRF2, which is known to promote the hybrid E/M phenotype and thus tumorigenic properties, through its antioxidant defences (Luo et al., 2018).

Katsuno et al demonstrated CSC properties of self-renewal and increased tumorigenicity in isolated ALDH+ cells from gastric cancer cell lines (Katsuno et al., 2012). High ALDH expression has also been correlated with poor clinical outcomes in pancreatic, ovarian and prostate cancers (Kuroda et al., 2013; Le Magnen et al., 2013; Fitzgerald and Mccubrey, 2014). Furthermore, acquired drug resistance in tumour cells is associated with transcriptional activation of ALDH1 expression (Yoshida et al., 1993). Early studies have investigated the utility of therapies targeting ALDH1 positive CSCs in breast, ovary and NSCLC (Li et al., 2008; Duan et al., 2014; Schech et al., 2015; Wu et al., 2015; MacDonagh et al., 2017). A phase II trial investigated the effect of administering Disulfiram—a potent ALDH inhibitor—in addition to standard chemotherapy to patients with NSCLC, demonstrating good drug tolerance and a prolonged survival (Nechushtan et al., 2015). Thus, ALDH1 holds great potential as a CSC target for novel drug therapies.

ALDH isoforms ALDH1A3 and ALDH1L1 have shown potential as prognostic markers and therapeutic targets in gastric cancer (Li et al., 2016), whilst Ajani et al showed that ALDH+ tumour cells from OAC and GEJA resection specimens were more resistant to chemoradiotherapy, as compared to tumour cells with low ALDH1 expression (Ajani et al., 2014; Honing et al., 2014). Brungs et al examined the significance of the expression of CD133, CD44 and ALDH1 in metastatic deposits of GEJA: CD44 and ALDH1 expression were both significantly associated with poorer OS, and CD44 positivity was identified as an independent prognostic marker (Brungs et al., 2019).

EpCAM

The epithelial molecular adhesion molecule (EpCAM) is a transmembrane glycoprotein present in most epithelial tissues that plays a role in cell adhesion, migration and differentiation (Imano et al., 2013). EpCAM is commonly expressed in gastric cancer, with one study demonstrating CSC characteristics within the EpCAM+ tumour population, but not in EpCAM+ tumour cells (Wenqi et al., 2009). Imano et al showed that peritoneal metastases of gastric cancer express higher levels of EpCAM, as compared with biopsy samples of the primary tumour, indicating that only gastric cancer cells with high EpCAM expression may metastasize to the peritoneum (Imano et al., 2013). Despite this, most gastric cancers are EpCAM+, thus it must be used in conjunction with other more specific markers in identification of gastric CSCs (Brungs et al., 2016). Sun et al demonstrated that resistance to treatment with Adriaamycin, Cisplatin and 5-FU (ACF) was associated with an increase in EpCAM and CD90 expression in OAC, suggesting a role for these putative CSC markers in establishing drug resistance (Sun et al., 2018).

miRNAs

A number of miRNAs have been linked to the expression of gastric CSCs. miR-196a-5p has been shown to be upregulated in CD44+ gastric CSCs, and to play a key role in EMT and invasion through targeting of the Smad4 signalling pathway (Pan et al., 2017). High miR-501-5p levels were associated with poor OS and were shown to induce a CSC-like phenotype in gastric cell lines through activation of Wnt/β-catenin signalling pathways (Fan et al., 2016). Upregulation of miR-132 in gastric CSCs was linked to chemoresistance (Zhang et al., 2017). These miRNAs hold great promise as a targetable molecule in the treatment of gastric cancer, yet extensive work is required to validate their prognostic significance and mechanisms of action.

miRNAs have also been implicated in the regulation of CSC traits in OAC tumour cells. Downregulation of miR-17-5p in OAC tumour cells with CSC traits was shown to produce a
differences in molecular biology of both primary tumours and metastatic deposits, as potential variations may render targeted therapies useful in different disease settings. Furthermore, an enhanced knowledge of the regulatory pathways and miRNAs governing CSCs in GEJA would both facilitate drug development programmes and improve clinical prognostication, thus helping to provide the best possible treatment for this patient population.

AUTHOR CONTRIBUTIONS

KD wrote the manuscript. A-MB, CR, and OS contributed to review and editing of the manuscript.

FUNDING

This review was funded, as part of a larger project, by small grants from the British Division of the International Academy of Pathology (Travel fellowship bursary and Glasgow 2020 educational fellowship), Trinity Translational Medicine Institute (Building Engagements in Health Research award) and Trinity College Dublin (Ray O’Meara research fund award).

ACKNOWLEDGMENTS

This review was funded by the British Division of the International Academy of Pathology, Trinity Translational Medicine Institute and Trinity College Dublin. The completion of this manuscript was facilitated by each of the named authors.

REFERENCES

Abdi, E., Latifi-Navid, S., Zahrı, S., Yazdanbod, A., and Pourfarzi, F. (2019). Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. Cancer Med. 8, 6114–6126. doi:10.1002/cam4.2497

Aires, A., Ocampo, S. M., Simões, B. M., Josefa Rodríguez, M., Cadenas, J. F., Couleaud, P., et al. (2016). Multifunctionalized iron oxide nanoparticles for selective drug delivery to CD44-positive cancer cells. Nanotechnology 27, 065103. doi:10.1088/0957-4484/27/6/065103

Ajani, J. A., Wang, X., Song, S., Suzuki, A., Taketa, T., Sudo, K., et al. (2014). ALDH-1 expression levels predict response or resistance to preoperative chemoradiation in resectable esophageal cancer patients. Mol. Oncol. 8, 142–9. doi:10.1016/j.molonc.2013.10.007

Al-Batran, S. E., Hofheinz, R. D., Pauligk, C., Kopp, H. G., Haag, G. M., Luley, K. B., et al. (2016). Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capcitabine in patients with resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol. 17, 1697–1708. doi:10.1016/S1470-2045(16)30531-9

Al-Batran, S. E., Homann, N., Pauligk, C., Goetzte, T. O., Meiler, J., Kasper, S., et al. (2019). Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capcitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-esophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 393, 1948–1957. doi:10.1016/S0140-6736(18)32557-1

Al-Hajj, M., Wicha, M. S., Benito-Hernandez, A., Morrison, S. J., and Clarke, M. F. (2003). Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. United States 100, 3983–3988. doi:10.1073/pnas.0530291100

Alakhova, D. Y., Zhao, Y., Li, S., and Kabanov, A. V. (2013). Effect of doxorubicin/pluronic SP1049C on tumorigenicity, aggressiveness, DNA methylation and stem cell markers in murine leukemia. PLoS One 8, e72238. doi:10.1371/journal.pone.0072238

Bass, A., Thorsson, V., Shmulevich, I., et al. (2014). Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–9. doi:10.1038/nature13480

Batlle, E., and Clevers, H. (2017). Cancer stem cells revisited. Nat. Med. 23, 1124–1134. doi:10.1038/nm.4409

Biering, E., Seinstra, D., De Wit, E., Kester, L., Van Der Velden, D., Maynard, C., et al. (2016). Plasticity between epithelial and mesenchymal states unlinks EMT from metastasis-enhancing stem cell capacity. Cell Rep. 14, 2281–2288. doi:10.1016/j.celrep.2016.02.034

Bierie, B., Pierce, S. E., Kroeger, C., Stover, D. G., Pattabiraman, D. R., Thiru, P., et al. (2017). Integrin-β4 identifies cancer stem cell-enriched populations of partially mesenchymal carcinoma cells. Proc. Natl. Acad. Sci. United States 114, E2337–E2346. doi:10.1073/pnas.1618298114

Bocci, F., Jolly, M.K., Tripathi, S.C., Aguilar, M., Hanash, S.M., Levine, H., et al. (2017). Numb prevents a complete epithelial-mesenchymal transition by modulating Notch signalling. J. R. Soc. Interface 14, 20170512. doi:10.1098/rsif.2017.0512

Bocci, F., Tripathi, S. C., Vilchez Mercedes, S. A., George, J. T., Casabar, J. P., Wong, P. K., et al. (2019). NRF2 activates a partial epithelial-mesenchymal transition and is maximally present in a hybrid epithelial/mesenchymal phenotype. Integr. Biol. (Camb). 11, 251–263. doi:10.1039/cintbio2021

Bonnet, D., and Dick, J. E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730–737. doi:10.1038/nm797-730

Brabla, T. (2012). EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 22, 699–701. doi:10.1016/j.ccr.2012.11.009
Imano, M., Itoh, T., Satou, T., Yasuda, A., Nishiki, K., Kato, H., et al., 2013. High expression of epithelial cellular adhesion molecule in peritoneal metastasis of gastric cancer. Target Oncol. 8, 231–5. doi:10.1007/s13277-012-0239-4

Janjigian, Y. Y., Sanchez-Vega, F., Jonsson, P., Chatila, W. K., Hechtman, J. F., Ku, G. Y., et al., 2018. Genetic predictors of response to systemic therapy in esophageal gastric cancer. Cancer Discov. 8, 49–58. doi:10.1158/2159-8290.CD-17-0787

Jian, B., Li, Z., Xiao, D., He, G., Bai, L., and Yang, Q., 2016. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol. 37, 8941–9. doi:10.1007/s13277-015-4727-x

Jolly, M. K., Somarelli, J. A., Sheth, M., Biddle, A., Tripathi, S. C., Armstrong, A. J., et al. (2019). Hybrid epithelial/mesenchymal phenotypes promote metastasis and therapy resistance across carcinomas. Pharmacol. Ther. 194, 161–184. doi:10.1016/j.pharmthera.2018.09.007

Jolly, M. K., Tripathi, S. C., Jia, D., Mooney, S. M., Celiktas, M., Hanash, S. M., et al., 2016. Stability of the hybrid epithelial/mesenchymal phenotype. Oncotarget 7, 27067–27084. doi:10.18632/oncotarget.8166

Joshi, S. S., Maron, S. B., and Catenacci, D. V., 2018. Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. Future Oncol. 14, 417–430. doi:10.2217/fon-2017-0436

Kalluri, R., and Weinberg, R. A. (2009). The basics of epithelial-mesenchymal transition. J. Clin. Invest. 119, 1420–8. doi:10.1172/JCI36185

Katsuno, Y., Ehtah, S., Yashiro, M., Yanagihara, K., Hirakawa, K., and Miyazono, K., 2012. Coordinated expression of REG4 and aldehyde dehydrogenase 1 regulating tumourigenic capacity of diffuse-type gastric carcinoma-initiating cells is inhibited by TGF-β. J. Pathol. 228, 391–404. doi:10.1002/path.4102

Kaufmann, M., Heider, K. H., Sinn, H. P., Von Minckwitz, G., and Langer, R., 2014. Tumor budding in upper gastrointestinal carcinoma. Nature 511, 169. doi:10.1038/nature13678

Kather, J., Lynam-Lennon, N., Heavey, S., Sommerville, G., Bibby, B. A., Ffrench, B., Quinn, L., et al. (2018). miR-17-5p inhibits tumor proliferation migration and chemoresistance in NSCLC. PLoS One 13, e0194401. doi:10.1371/journal.pone.0194401

Khan, A. Q., Ahmed, E. I., Elareer, N. R., Junejo, K., Steinhoff, M., and Uddin, S., 2014. miRNA-219-3p inhibits tumor proliferation migration and chemoresistance in human cancer. Cancer Res. 74, 2630–7. doi:10.1158/0008-5472.CAN-13-2309

Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., et al. (2015). PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520. doi:10.1056/NEJMoa1500596

Le Magnen, C., Bubendorf, L., Rentsch, C. A., Mengus, C., Gsponer, J., Zellweger, T., et al. (2013). Characterization and clinical relevance of ALDH1bright populations in prostate cancer. Clin. Cancer Res. 19, 5361–71. doi:10.1158/1078-0432.CCR-12-2857

Levina, V., Marrangoni, A. M., Demarco, R., Gorelik, E., and Lokshin, A. E., 2008. Generation of breast cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3, e3077. doi:10.1371/journal.pone.0003077
Rubenstein, J. H., and Shaheen, N. J. (2015). Epidemiology, diagnosis, and management of esophageal adenocarcinoma. *Br J Surg*. 97, 828–842. doi:10.1053/j.bjs.2014.08.065

Sun, X., Martin, R. C. G., Zheng, Q., Farmer, R., Pandit, H., Li, X., et al. (2018). Drug-induced expression of EpCAM contributes to therapy resistance in esophageal adenocarcinoma. *Cell Oncol. (Dordr)* 41, 651–662. doi:10.1007/s13402-018-0399-z

Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. *Cell* 126, 63–76. doi:10.1016/j.cell.2006.07.002

Thanakomy, A. P., Saxena, K., Murali, R., Jolly, M. K., and Nair, R. (2020). Cancer stem cell plasticity: A deadly deal. *Front. Mol. Biosci.* 7, 79. doi:10.3389/fmolb.2020.00079

Thapa, R., and Wilson, G. D. (2016). The importance of CD44 as a stem cell biomarker and therapeutic target in cancer. *Stem Cells Int.* 2016, 2087204. doi:10.1186/s12955-016-0252-6

Tian, Y., Luo, A., Cai, Y., Su, Q., Ding, F., Chen, H., et al. (2010). MicroRNA-10b promotes migration and invasion through FLK4 in human esophageal cancer cell lines. *J Biol Chem.* 285, 7986–7994. doi:10.1074/jbc.M110.026877

Tomita, H., Tanaka, K., Tanaka, T., and Hara, A. (2016). Aldehyde dehydrogenase 1A1 in stem cells and cancer. *Oncotarget* 7, 11088–32. doi:10.18632/oncotarget.9579

Toyokawa, G., Seto, T., Takenoyama, M., and Ichinose, Y. (2015). Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary? *Cancer Metastasis Rev.* 34, 797–805. doi:10.1007/s10555-015-9592-y

Tripathi, S., Chakraborty, P., Levine, H., and Jolly, M. K. (2020). A mechanism for epithelial-mesenchymal heterogeneity in a population of cancer cells. *PLoS Comput. Biol.* 16, e1007619. doi:10.1371/journal.pcbi.1007619

Tse, J. C., and Kalluri, R. (2007). Mechanisms of metastasis: epithelial-to-mesenchymal transition and contribution of tumor microenvironment. *J. Cell Biochem.* 101, 816–29. doi:10.1002/jcb.21215

Vasan, N., Basgila, J., and Hyman, D. M. (2019). A view on drug resistance in cancer. *Nature* 575, 299–309. doi:10.1038/s41586-019-1730-1

Vassalli, G. (2019). Aldehyde dehydrogenases: not just markers, but functional regulators of stem cells. *Stem Cells Int.* 2019, 3904645. doi:10.1155/2019/3904645

Visvader, J. E., and Lindeman, G. J. (2012). Cancer stem cells: current status and evolving complexities. *Cell Stem Cell* 10, 717–28. doi:10.1016/j.stem.2012.05.007

Wang, T., Hou, J., Li, Z., Zheng, Z., Wei, J., Song, D., et al. (2017). miR-15a-3p and miR-16-1-3p negatively regulate twist1 to repress gastric cancer cell invasion and metastasis. *Int. J. Biol. Sci.* 13, 122–134. doi:10.7150/ijbs.14770

Wang, Y., Zhao, Y., Herbst, A., Kalinski, T., Qin, J., Wang, X., et al. (2016). miR-221 mediates chemoresistance of esophageal adenocarcinoma by direct targeting of DKK2 expression. *Ann. Surg.* 264, 804–814. doi:10.1097/SLA.0000000000001928

Wang, Y. Y., Li, L., Ye, Z. Y., Zhao, Z. S., and Yan, Z. L. (2015). MicroRNA-10b promotes migration and invasion through Hoxd10 in human gastric cancer. *World J. Surg. Oncol.* 13, 259. doi:10.1186/s12957-015-0673-8

Watanabe, K., Villarreal-Ponce, A., Sun, P., Salmans, M. L., Fallahi, M., Andersen, B., et al. (2014). Mammary morphogenesis and regeneration require the inhibition of EMT at terminal end buds by Ovol2 transcriptional repressor. *Dev. Cell* 29, 59–74. doi:10.1016/j.devcel.2014.03.006

Watanabe, T., Okumura, T., Hirano, K., Yamaguchi, T., Sekine, S., Nagata, T., et al. (2017). Circulating tumor cells expressing cancer stem cell marker CD44 as a diagnostic biomarker in patients with gastric cancer. *Oncol. Lett.* 13, 281–288. doi:10.3892/ol.2016.5432

Shibue, T., and Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat. Rev. Clin. Oncol.* 14, 611–629. doi:10.1038/nrclinonc.2017.44

Siewert, J. R., and Stein, H. J. (1998). Classification of adenocarcinoma of the esophagogastric junction. *Br J Surg.* 85, 1457–9. doi:10.1016/S0007-0994(98)80490.x

Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncoogene* 29, 4741–4751. doi:10.1016/j.onco.2010.04.020

Skubit, A. P., Taras, E. P., Boylan, K. L., Waldron, N. N., Oh, S., Panoskaltsis-Mortari, A., et al. (2013). Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. *Gynecol Oncol.* 130, 579–87. doi:10.1016/j.ygyno.2013.05.027

Shibue, T., and Weinberg, R. A. (2017). EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. *Nat. Rev. Clin. Oncol.* 14, 611–629. doi:10.1038/nrclinonc.2017.44

Siewert, J. R., and Stein, H. J. (1998). Classification of adenocarcinoma of the esophagogastric junction. *Br J Surg.* 85, 1457–9. doi:10.1016/S0007-0994(98)80490.x

Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncoogene* 29, 4741–4751. doi:10.1016/j.onco.2010.04.020

Skubit, A. P., Taras, E. P., Boylan, K. L., Waldron, N. N., Oh, S., Panoskaltsis-Mortari, A., et al. (2013). Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression. *Gynecol Oncol.* 130, 579–87. doi:10.1016/j.ygyno.2013.05.027

Singh, A., and Settleman, J. (2010). EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. *Oncoogene* 29, 4741–4751. doi:10.1016/j.onco.2010.04.020
Wei, S. C., Fattet, L., Tsai, J. H., Guo, Y., Pai, V. H., Majeski, H. E., et al. (2015). Matrix stiffness drives epithelial-mesenchymal transition and tumour metastasis through a TWIST1-G3BP2 mechanotransduction pathway. Nat. Cell Biol. 17, 678–88. doi:10.1038/ncb3157

Wen, L., Chen, X. Z., Yang, K., Chen, Z. X., Zhang, B., Chen, J. P., et al. (2013). Prognostic value of cancer stem cell marker CD133 expression in gastric cancer: a systematic review. PLoS One 8, e59154. doi:10.1371/journal.pone.0059154

Wenqi, D., Li, W., Shanshan, C., Bei, C., Yafei, Z., Feihu, B., et al. (2009). EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer. J. Cancer Res. Clin. Oncol. 135, 1277–85. doi:10.1007/s00432-009-0569-5

Wu, Y., and Wu, P. Y. (2009). CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 18, 1127–34. doi:10.1089/scd.2008.0338

Wu, Y. H., Chiu, W. T., Young, M. J., Chang, T. H., Huang, Y. F., and Chou, C. Y. (2015). Solanum incanum extract downregulates aldehyde dehydrogenase 1-mediated stemness and inhibits tumor formation in ovarian cancer cells. J. Cancer 6, 1011–1019. doi:10.7150/jca.12738

Xi, X. P., Zhuang, J., Teng, M. J., Xia, L. J., Yang, M. Y., Liu, Q. G., et al. (2016). MicroRNA-17 induces epithelial-mesenchymal transition consistent with the cancer stem cell phenotype by regulating CYP7B1 expression in colon cancer. Int J Mol Med. 38, 499–506. doi:10.3892/ijmm.2016.2624

Xia, P., Song, C. L., Liu, J. F., Wang, D., and Xu, X. Y. (2015). Prognostic value of circulating CD133(+) cells in patients with gastric cancer. Cell Prolif. 48, 311–7. doi:10.1111/cpr.12175

Ychou, M., Boige, V., Pignon, J. P., Conroy, T., Bouché, O., Lebreton, G., et al. (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 29, 1715–21. doi:10.1200/JCO.2010.33.0597

Yu, J. M., Sun, W., Hua, F., Xie, J., Lin, H., Zhou, D. D., et al. (2015). BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett. 365, 190–200. doi:10.1016/j.canlet.2015.05.029

Yoon, C., Park, D. J, Schmidt, B., Thomas, N. J., Lee, H. J., Kim, T. S., et al. (2014). CD44 expression denotes a subpopulation of gastric cancer cells in which Hedgehog signaling promotes chemotherapy resistance. Clin. Cancer Res. 20, 3974–88. doi:10.1158/1078-0432.CCR-14-0011

Yu, J. M., Sun, W., Hua, F., Xie, J., Lin, H., Zhou, D. D., et al. (2015). BCL6 induces EMT by promoting the ZEB1-mediated transcription repression of E-cadherin in breast cancer cells. Cancer Lett. 365, 190–200. doi:10.1016/j.canlet.2015.05.029

Zanoni, A., Verlato, G., Baiocchi, G. L., Casella, F., Cossu, A., D’ignazio, A., et al. (2018). Siewert III esophagogastric junction adenocarcinoma: does TNM 8th save us? Updates Surg. 70, 241–249. doi:10.1007/s13304-018-0537-1

Zhang, L., Guo, X., Zhang, D., Fan, Y., Qin, L., Dong, S., et al. (2017). Upregulated miR-132 in Lgr5(+) gastric cancer stem cell-like cells contributes to cisplatin-resistance via SIRT1/CREB/ABCG2 signaling pathway. Mol. Carcinog. 56, 2023–2034. doi:10.1002/mc.22656

Zlobec, I., and Lugli, A. (2010). Epithelial mesenchymal transition and tumor budding in aggressive colorectal cancer: tumor budding as oncotarget. Oncotarget 1, 651–661. doi:10.18632/oncotarget.199

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Dinneen, Baird, Ryan and Sheils. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.